# Impact of comorbidities in patients with erosive hand osteoarthritis (EHOA), a monocentric study

**Authors:** S. Bindoli, G. Cozzi, C. Benvoluti, M. Lorenzin, S. Vio, P. Sfriso, M. Favero, R. Ramonda

PMC · DOI: 10.3389/fragi.2026.1748066 · Frontiers in Aging · 2026-02-12

## TL;DR

This study explores how comorbidities like osteoporosis and overweight affect the severity and progression of erosive hand osteoarthritis in patients.

## Contribution

The study provides new insights into the relationship between systemic comorbidities and clinical outcomes in erosive hand osteoarthritis patients.

## Key findings

- Overweight correlates with joint space narrowing in EHOA patients.
- Osteoporosis severity correlates with higher pain and functional impairment scores.
- Comorbidities are linked to greater structural damage in EHOA.

## Abstract

Erosive hand osteoarthritis (EHOA) is a severe and rapidly progressing form of osteoarthritis that has been linked to systemic comorbidities (i.e., metabolic bone and cardiovascular diseases). The object of this study is to retrospectively evaluate the impact of comorbidities (i.e., osteoporosis, diabetes and overweight) on the clinical course and radiographic findings in a cohort of EHOA patients.

This is a retrospective cross-sectional study. Patients underwent clinical assessments and completed the VAS scale, the AUSCAN and DREISER questionnaires. Metabolic, cardiovascular, and bone health data were collected. Radiographic features—osteophytes, joint space narrowing, malalignment, erosions, sclerosis, and subchondral cysts—were evaluated using the Altman system. Comorbidities were assessed using the Charlson Comorbidity Index, whereas metabolic syndrome, diabetes, and osteoporosis were defined according to the ATP III and WHO criteria. Statistical analysis was conducted via Spearman’s correlation, using GraphPad Prism 9.1.0, with significance set at p < 0.05.

Eighty-seven patients (88.5% female, mean age 63.17 ± 8.85) were included. Among comorbidities, 76.8% had at least one risk factor; BMI correlated with joint space narrowing (r = 0.22, p = 0.04). Severity of femoral and lumbar osteoporosis correlated with AUSCAN and DREISER scores; FRAX scores significantly correlated with several radiographic features of EHOA; VAS correlated with swollen and painful joint count, with AUSCAN and DREISER scores and with osteophytosis. Disease duration correlated with overall radiographic damage.

Cardiovascular and metabolic bone comorbidities, especially overweight and osteoporosis, appear to be associated with higher pain burden, functional impairment, and greater structural damage in EHOA patients.

## Linked entities

- **Diseases:** osteoporosis (MONDO:0005298), diabetes (MONDO:0005015), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}
- **Diseases:** type 2 diabetes (MESH:D003924), joint degeneration (MESH:D009410), Sclerosis (MESH:D012598), BMD loss (MESH:D001851), hypercholesterolemia (MESH:D006937), Malalignment (MESH:D017760), heart failure (MESH:D006333), degradation (MESH:D055959), Obesity (MESH:D009765), functional disability (MESH:D003291), stroke (MESH:D020521), TJ (MESH:D063806), overweight (MESH:D050177), dementia (MESH:D003704), neurological disorders (MESH:D009461), ankylosis (MESH:D000844), DIP joints (MESH:D010003), metabolic (MESH:D008659), fragility fracture (MESH:D005600), functional impairment (MESH:D003072), disability (MESH:D009069), hypertriglyceridemia (MESH:D015228), cartilage (MESH:D002357), femoral or spinal fractures (MESH:D005264), cysts (MESH:D003560), bone fragility (MESH:C536063), CCI (MESH:C566784), comorbidity (MESH:D004194), Inflammatory (MESH:D007249), liver disease (MESH:D008107), rheumatoid arthritis (MESH:D001172), MetS (MESH:D024821), hyperglycemia (MESH:D006943), Fracture (MESH:D050723), pain (MESH:D010146), stiffness (MESH:C566112), hypertension (MESH:D006973), chronic respiratory diseases (MESH:D012140), dyslipidemia (MESH:D050171), hip fracture (MESH:D006620), osteophyte (MESH:D054850), myocardial infarction (MESH:D009203), Subchondral cysts (MESH:D001845), Cardiovascular comorbidities (MESH:D002318), Diabetes (MESH:D003920), peptic ulcer disease (MESH:D010437), cancer (MESH:D009369), Erosions (MESH:D014077), bone diseases (MESH:D001847), joint pain (MESH:D018771), osteophytosis (MESH:D013128), SJ (MESH:D007592), chronic kidney disease (MESH:D051436), OP (MESH:D010024), radiographic damage (MESH:D000089202), insulin resistance (MESH:D007333), osteoporotic (MESH:D058866)
- **Chemicals:** metformin (MESH:D008687), alendronate (MESH:D019386), zoledronic acid (MESH:D000077211), neridronate (MESH:C053389), alcohol (MESH:D000438), glucosamine sulfate (MESH:D005944), glucose (MESH:D005947), Cholesterol (MESH:D002784), bisphosphonates (MESH:D004164), risedronate (MESH:D000068296), blood glucose (MESH:D001786), hyaluronic acid (MESH:D006820), calcium (MESH:D002118), clodronate (MESH:D004002), ACEV (-), chondroitin sulfate (MESH:D002809), Vitamin D (MESH:D014807), teriparatide (MESH:D019379), denosumab (MESH:D000069448), phosphate (MESH:D010710), 25-hydroxyvitamin D (MESH:C104450), uric acid (MESH:D014527), triglyceride (MESH:D014280)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935983/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12935983/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935983/full.md

---
Source: https://tomesphere.com/paper/PMC12935983